Rana Al-Hallaq

Rana Al-Hallaq has a long and varied work experience. In 2021, they became the Director Board of Directors of Triplet Therapeutics, Observer Board of Directors of Jnana Therapeutics, Director Board of Directors of ReCode Therapeutics, Director Board of Directors of Vivet Therapeutics, Director Board of Directors of RefleXion Medical, and Director Board of Directors of NY BIO. In 2020, they were the Director Board of Directors of Montis Biosciences. In 2019, they were the Observer Board of Directors of Arkuda Therapeutics and the Director Board of Directors of Autifony Therapeutics. From 2015 to 2021, they were a Partner at Pfizer Ventures and held various roles, including Executive Director of Pfizer Worldwide Business Development, Senior Director and Partner of Pfizer Ventures, Senior Director and Principal of Pfizer Ventures, Director of Business Development, and Early Candidate Clinical Lead.

Rana Al-Hallaq received a BA in Biology from Hamilton College between 1992 and 1996. Rana then went on to earn a PhD in Neuroscience from Georgetown University between 1997 and 2002.